Evidence map›Paper›PMID 41256870›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2025

Ellipsoid Zone Hyporeflectivity as an Early Sign of Non-Reversible Hydroxychloroquine Retinopathy: A Case Series.

Jonathan D Groothoff, David J Browning

Abstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jonathan D GroothoffWake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID 0009-0006-7419-6781
David J BrowningWake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0002-0442-8122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The purpose of this study was to evaluate the progression of hydroxychloroquine (HCQ) retinopathy following parafoveal loss of the ellipsoid zone (EZ) without retinal pigment epithelium damage (RPE). Methods: This was a single-center retrospective case series of patients with hydroxychloroquine retinopathy who presented between 2012 and 2023 and in whom the drug was stopped prior to damage of the RPE. Patient imaging from the time of HCQ discontinuation to the most recent follow up appointment was reviewed to assess for retinopathy progression, and spectral domain optical coherence tomography (SD-OCT) images were analyzed using ImageJ2 to quantify ellipsoid zone damage. Results: Five patients met the criteria for inclusion in this study. All patients were female, with a mean age of 69.5 ± 12.2 years. Patients had been taking HCQ for 18.2 years on average (range: 5-32 years). 40% of patients were overdosed according to real weight guidelines and 60% by ideal weight guidelines. All patients demonstrated worsening of retinopathy following drug discontinuation. The length of parafoveal zones of EZ hyporeflectivity on SD-OCT increased by an average of 26.8 ± 8.6% in right eyes and 22.5 ± 15.0% in left eyes over an average follow-up period of 31.4 months (range 8-71 months). Conclusion: Progression of HCQ retinopathy can occur even when HCQ is discontinued before RPE damage. Ophthalmologists should be aware of the risks associated with HCQ use following damage to the EZ. The acknowledged threshold at which irreversible progression of retinopathy is predicted despite cessation of the drug may need to be reconsidered and shifted earlier than RPE loss.

Indexed as

ellipsoid zonehydroxychloroquinehydroxychloroquine retinopathyretinal pigmented epitheliumspectral domain OCT

Identifiers

PMID41256870
PMCPMC12620907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.